T. Rowe Price Investment Management, Inc., a registered investment adviser, initiated a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 9,108,019 shares of the Healthcare company, valued at approximately $720.5M as of the filing date.
Ionis Pharmaceuticals, Inc.'s stock currently trades at $84.64 with a market capitalization of $12.6B.